COVID-19. COVID-19 , virus identified
Conditions
Interventions
Intervention 1: Intervention group: Includes 22 patients with COVID-19 who, in addition to their usual treatments, will take 3*30 mg zinc capsules daily for 2 weeks (14 days) after meals. Intervention
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 60 Years
Inclusion criteria
Inclusion criteria: Being 20 to 60 years old Detection of COVID-19 based on PCR test and ward admission Willingness to participate in the study Intravenous daily intake of 8 mg dexamethasone
Exclusion criteria
Exclusion criteria: Taking antibiotics and vitamin D. Advanced Respiratory Distress Syndrome leading to intubation or hospitalization in the intensive care unit History of alcohol and tobacco use
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum C-Reactive Protein level. Timepoint: The first day and the last day of the intervention. Method of measurement: blood analysis.;Serum Interleukin-6 level. Timepoint: The first day and the last day of the intervention. Method of measurement: Using blood, serum IL-6 value in Picograms per deciliter by Kit.;Blood leukocyte count. Timepoint: The first day and the last day of the intervention. Method of measurement: blood analysis.;Total Lymphocyte Count. Timepoint: The first day and the last day of the intervention. Method of measurement: blood analysis.;Absolute neutrophil count. Timepoint: The first day and the last day of the intervention. Method of measurement: blood analysis. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contact??Seyed Morteza Seyed khamoushi
Tehran University of Medical Sciences
Outcome results
None listed